


VOLUME 84 ISSUE 1, MAY 2026



# EASL CONGRESS

Barcelona Spain  
27–30 May **2026**



# ABSTRACT BOOK

#EASLCongress

[easlcongress.eu](http://easlcongress.eu)

# JOURNAL OF HEPATOLOGY

VOLUME **84**, SUPPLEMENT **S1**, PAGES **S1–S1108**

Abstract Book of EASL Congress 2026  
27–30 May 2026, Barcelona, Spain


Publication of this Abstract supplement was supported by the European Association for the Study of the Liver (EASL)

ELSEVIER



# EASL CONGRESS

London United Kingdom  
16–19 June 2027



#EASLCongress

[easlcongress.eu](http://easlcongress.eu)

**SAVE THE DATE!**



**EASL** GUIDELINES



**2.0**


# Your essential app for advanced liver care



Consult EASL Clinical Practice Guidelines anytime, anywhere.



Expand your knowledge with continuously updated resources and tools.




Discover EASL Policy Statements and Policy Dialogues.





**EASL**<sup>™</sup> The Home of  
Hepatology



# Let's unite hepatology!

Discover your  
membership benefits!



Become a member >

# JOURNAL OF HEPATOLOGY

VOLUME 84, SUPPLEMENT 1, PAGES S1–S1108

## CONTENTS

<b>Oral Presentations</b> .....	S1
GENERAL SESSION I .....	S1
GENERAL SESSION II .....	S4
Late breakers oral session .....	S7
Hepatocyte biology and fibrosis .....	S11
Immune-mediated I .....	S13
Liver tumours – experimental .....	S17
MASLD: Clinical and therapeutical aspects I .....	S19
Interprofessional forum .....	S21
Public health .....	S23
Alcohol .....	S26
Basic Science MASLD .....	S28
Cirrhosis – Clinical and experimental I .....	S30
Cirrhosis – Clinical and experimental II .....	S33
Liver tumours – Clinical .....	S36
Rare liver diseases .....	S39
Regeneration and gut communication .....	S41
Viral hepatitis B/D – Current therapies .....	S43
Viral hepatitis B/D – New therapies .....	S47
Basic viral hepatitis and immunology .....	S49
Cirrhosis – Clinical and experimental III .....	S52
Immune mediated II .....	S55
Liver transplantation .....	S59
MASLD: Clinical and therapeutical aspects II .....	S62
Viral hepatitis – Clinical aspects .....	S65
EASL Clinical Practice Guidelines on management of primary biliary cholangitis and PBC abstracts .....	S67

<b>Poster Presentations</b> .....	S69
Late-breaker Posters .....	S69
Acute liver failure and drug induced liver injury – Clinical .....	S88
Acute liver failure and drug induced liver injury – Experimental and pathophysiology .....	S99
Alcohol-related liver disease and MetALD – Clinical .....	S108
Alcohol-related liver disease and MetALD – Experimental and pathophysiology .....	S129
Cirrhosis and its complications – ACLF and Critical illness .....	S141
Cirrhosis and its complications – Experimental and pathophysiology .....	S162
Cirrhosis and its complications – Other clinical complications except ACLF and critical illness .....	S184
Fibrosis – Stellate cell biology .....	S229
General Hepatology (including non-invasive liver assessment) .....	S246
Gut microbiota and liver disease – Liver-organ crosstalk .....	S260
Hepatocyte biology .....	S270
Immune-mediated and cholestatic – Experimental and pathophysiology .....	S281
Immune-mediated and cholestatic disease – Clinical aspects .....	S294
Liver development and regeneration .....	S357
Liver immunology .....	S362
Liver transplantation and hepatobiliary surgery – Clinical .....	S374
Liver transplantation and hepatobiliary surgery – Experimental and pathophysiology .....	S418
Liver tumours – Clinical aspects except therapy .....	S422
Liver tumours – Experimental and pathophysiology .....	S453
Liver tumours – Therapy .....	S490
MASLD – Clinical aspects except therapy .....	S515
MASLD – Diagnostics and non-invasive assessment .....	S558
MASLD – Experimental and pathophysiology .....	S627
MASLD – Therapy .....	S678
Nurses and Allied Health Professionals – Research project .....	S702
Nurses and Allied Health Professionals – Clinical – service development or improvement project .....	S710
Portal Hypertension (cirrhosis and non-cirrhosis) .....	S719
Public Health – Except Viral Hepatitis .....	S758
Public Health – Viral Hepatitis .....	S797
Rare liver diseases (including paediatric and genetic) – Clinical .....	S827
Rare liver diseases (including paediatric and genetic) – Experimental and pathophysiology .....	S852
Viral hepatitis – Clinical, except HBV, HDV and HCV .....	S864

Viral Hepatitis – Experimental and pathophysiology .....	S868
Viral hepatitis B and D – Clinical aspects .....	S897
Viral hepatitis B and D – Current therapies .....	S934
Viral hepatitis B and D – New therapies, unapproved therapies or strategies .....	S956
Viral hepatitis C – Clinical aspects including follow up after SVR .....	S966
Viral hepatitis C – Therapy and resistance .....	S979
Author Index .....	S982
Disclosures: no commercial relationships .....	S1099
Disclosures: commercial relationships .....	S1104
Reviewers list .....	S1108

**Registration of Clinical Trials**

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004; 351:1250–1251 and *New Engl J Med* 2005; 352:2437–2438.

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

 **ScienceDirect**  
for online access via your library

early (M1) increase in HA after TIPS may reflect reduced sinusoidal clearance and indicates higher risks of HE, ACLF, and death.

**THU-465**

**Splenic hyperkinetic syndrome: a universal driver of cirrhotic and non-cirrhotic portal hypertension**

Sergii Kozlov<sup>1</sup>, Ihor Kolosovych<sup>1</sup>, Nadiia Yakovenko<sup>1</sup>, Natalia Leshchynska<sup>1</sup>. <sup>1</sup>*Bogomolets National medical university, Kyiv, Ukraine*  
Email: sergiinikol@gmail.com

**Background and aims:** Portal hypertension (PH) is attributed to increased intrahepatic resistance. However, the role of splanchnic hyperdynamic circulation, specifically excessive inflow, remains underappreciated. We hypothesized that splenic arterial hyperperfusion acts as a universal hemodynamic driver in PH - regardless of etiology - creating a volume overload that the portal system cannot accommodate. This study aims to evaluate the relations between splenic arterial inflow and portal venous flow in patients with established cirrhotic and non-cirrhotic PH.

**Method:** The study included three groups: 1) 47 patients with liver cirrhosis and cirrhotic PH (CPH); 2) 7 patients with non-cirrhotic PH (NCPH); 3) a control group of 41 healthy volunteers (CG). All patients of the CPH and NCPH groups presented with esophageal and gastric varices and a history of variceal bleeding(s). All participants underwent a Doppler ultrasound assessment. We analyzed spleen volume, splenic artery parameters (PSV, EDV, RI), and maximum linear flow velocities ( $V_{max}$ ) in the splenic vein and the main portal vein (PV) trunk.

**Results:** Patients in the CPH group presented with significant splenomegaly ( $811.6 \pm 342.2$  cm/s vs.  $146.35 \pm 56.27$  cm<sup>3</sup> in controls;  $p < 0.001$ ) and a severe hyperdynamic state. PSV in the SA was up to  $150.84 \pm 43.57$  cm/s compared to  $85.43 \pm 26.72$  cm/s in controls ( $p < 0.001$ ), with EDV nearly doubling. This arterial surge led to venous overload (SV velocity was  $34.1 \pm 15.55$  cm/s vs.  $23.54 \pm 6.16$  cm/s in CG,  $p < 0.001$ ). A paradoxical deceleration was observed in the main portal vein ( $29.06 \pm 9.43$  cm/s vs.  $35.67 \pm 10.53$  cm/s in controls,  $p < 0.01$ ). This «hemodynamic mismatch» is a result of an existing left gastric vein shunt that feeds gastric/esophageal varices, effectively reducing velocity in the main portal trunk.

**Conclusion:** Our findings reveal distinct hemodynamic changes in patients with clinically significant portal hypertension: massive splenic artery inflow leads to accelerated venous output, which is then diverted to portosystemic collaterals (gastroesophageal varices). This pattern was consistent across both CPH and NCPH cohorts, suggesting that excessive splenic blood flow is a universal pathogenic driver of portal hypertension development. Targeting splenic inflow (e.g. via NSBB treatment, embolization or both) addresses this fundamental mechanism of collateral filling and may be effective regardless of the portal hypertension etiology.

**THU-466**

**The differential effects of terlipressin on serum sodium trajectories are mediated by ascites status, treatment indication and baseline sodium**

Dorothy Liu<sup>1</sup>, Jacqueline Balassone<sup>2</sup>, Royston Fernandes<sup>3</sup>, Sophie Testro<sup>4</sup>, Dinesh Pandey<sup>5</sup>, Penelope Hey<sup>1</sup>, Karl Vaz<sup>6</sup>, Marie Sinclair<sup>1</sup>, Avik Majumdar<sup>1</sup>, Adam Testro<sup>6</sup>. <sup>1</sup>*Victorian Liver Transplant Unit, Austin Health, Australian Centre for Transplantation Excellence and Research (ACTER), Austin Health, Department of Medicine (Austin Precinct), The University of Melbourne, Melbourne, Australia;* <sup>2</sup>*Victorian Liver Transplant Unit, Austin Health, Australian Centre for Transplantation Excellence and Research (ACTER), Austin Health, Department of Pharmacy, Austin Health, Melbourne, Australia;* <sup>3</sup>*Victorian Liver Transplant Unit, Austin Health, Australian Centre for Transplantation Excellence and Research (ACTER), Austin Health, Melbourne, Australia;* <sup>4</sup>*Faculty of Science, The University of Melbourne, Melbourne, Australia;* <sup>5</sup>*Business Intelligence Unit, Austin Health,*

*Melbourne, Australia;* <sup>6</sup>*Victorian Liver Transplant Unit, Austin Health, Australian Centre for Transplantation Excellence and Research (ACTER), Austin Health, Department of Surgery (Austin Precinct), The University of Melbourne, Melbourne, Australia*  
Email: dorothyliu22@gmail.com

**Background and aims:** Terlipressin is an established therapy for complications of portal hypertension, however concerns persist regarding its potential to cause hyponatremia. Data describing serum sodium (sNa) trajectories during terlipressin therapy across clinical phenotypes are limited.

**Method:** We conducted a single-centre, retrospective study of consecutive adult patients treated with terlipressin between 2013 and 2024. Patients receiving treatment for <2 days, with intrinsic renal disease or on renal replacement therapy were excluded. Linear mixed-effects modelling was used to analyse sNa trajectories for up to 14 days of treatment, stratified by ascites status, treatment indication and baseline sNa. Patients with a  $\geq 5\%$  sNa decrease from baseline were also evaluated. Severe hyponatremia was defined as  $sNa < 125$  mmol/L.

**Results:** Across the entire cohort of 414 patients, sNa was observed to increase during terlipressin therapy (adjusted mean sNa change from baseline to day 14: 4 mmol/L, 95% CI 3 to 6,  $p < 0.001$ ). However, changes in sNa differed according to the presence or absence of ascites, baseline sNa, and the indication for use (acute variceal bleeding [AVB]). Adjusted sNa increased over time in patients with ascites but remained stable in those without ascites. Similarly, adjusted sNa increased over time in baseline hyponatremic patients but remained stable in baseline normonatremic patients. An early decline in adjusted sNa was observed in patients with baseline normonatremia, no ascites, and treated with terlipressin for AVB (adjusted mean sNa change from baseline to day 5:  $-7$  mmol/L, 95% CI  $-9$  to  $-4$ ,  $p < 0.001$ ). 44 patients (11%) experienced a  $\geq 5\%$  decline in sNa relative to baseline and were more likely to have higher baseline sNa, lower baseline serum creatinine, lower Model for End-Stage Liver Disease (MELD) and be treated for AVB ( $p < 0.001$ ). Baseline sNa and MELD were independently associated with a  $\geq 5\%$  decline in sNa from baseline (adjusted OR 1.13,  $p < 0.001$  and adjusted OR 0.91,  $p < 0.004$ , respectively). Severe hyponatremia was rare, occurring in 10 patients (2%).

**Conclusion:** Whilst at a population level terlipressin increased sNa, we observed differential effects on sNa according to ascites status, treatment indication and baseline sNa. Clinically significant hyponatremia was uncommon and occurred mainly in patients without ascites, with higher baseline sNa and AVB as the indication for terlipressin, highlighting the need for closer monitoring in this subgroup during therapy.

**THU-467**

**Liver stiffness measurement as an alternative to liver biopsy to rule-out cirrhosis over PSVD in patients with portal hypertension**

Ann T Ma<sup>1</sup>, Lorenz Balcar<sup>2</sup>, Lucile Moga<sup>1,3</sup>, Fanny Turon<sup>4,5,6</sup>, Georg Kramer<sup>2</sup>, Georg Semmler<sup>2</sup>, Ignasi Olivas<sup>7,8</sup>, María Carlota Londoño<sup>7,8</sup>, Lukas Burghart<sup>9</sup>, Benedikt Hofer<sup>10</sup>, Pierre Nahon<sup>11</sup>, Nathalie Ganne-Carrié<sup>11</sup>, Vlad Ratziu<sup>12</sup>, Aurélie Plessier<sup>1,3</sup>, Bernhard Scheiner<sup>2</sup>, Virginia Hernández-Gea<sup>4,5,6</sup>, Laure Elkrief<sup>13</sup>, Pierre-Emmanuel Rautou<sup>1,3</sup>. <sup>1</sup>*Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France;* <sup>2</sup>*Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria;* <sup>3</sup>*Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria;* <sup>4</sup>*Centre de recherche sur l'inflammation, Université Paris-Cité, Inserm, Paris, France;* <sup>5</sup>*Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, European Reference Network on Rare Liver Disorders (ERN-RareLiver), CSUR Centro de referencia del Sistema Nacional de Salud en Enfermedad Hepática Vasculare Compleja en adultos, Barcelona, Spain;* <sup>6</sup>*Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi*